enGene Holdings Inc. (NASDAQ:ENGN) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts rate enGene a "Moderate Buy": 10 analysts cover the stock (1 sell, 1 hold, 7 buy, 1 strong buy) with an average 1‑year price target of $22.86, versus the recent share price around $7.07, implying significant upside potential.
• Company snapshot: enGene is a clinical‑stage biotech developing EG‑70 for non‑muscle invasive bladder cancer; it reported Q results of ($0.44) EPS beating estimates, has very strong liquidity (quick/current ratio 11.75), a market cap of $473.6M, and institutional investors own about 64.2% of the stock after several large stake increases.

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $22.8571.

Several research analysts recently commented on the company. Oppenheimer lowered their target price on enGene from $33.00 to $30.00 and set an "outperform" rating for the company in a research note on Wednesday, March 11th. Guggenheim reiterated a "buy" rating on shares of enGene in a research note on Tuesday, March 10th. Citigroup reissued a "market outperform" rating on shares of enGene in a research report on Monday, January 5th. HC Wainwright restated a "buy" rating and set a $25.00 target price on shares of enGene in a research note on Monday, March 9th. Finally, Wall Street Zen raised shares of enGene from a "sell" rating to a "hold" rating in a report on Saturday, March 14th.

enGene Price Performance

enGene stock opened at $7.07 on Thursday. The company has a quick ratio of 11.75, a current ratio of 11.75 and a debt-to-equity ratio of 0.09. enGene has a 52-week low of $2.65 and a 52-week high of $12.25. The firm has a market cap of $473.62 million, a PE ratio of -3.14 and a beta of -0.29. The company's 50 day moving average is $9.17 and its two-hundred day moving average is $8.28.

enGene (NASDAQ:ENGN - Get Free Report) last posted its quarterly earnings results on Monday, March 9th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.11. On average, research analysts expect that enGene will post -1.56 EPS for the current fiscal year.

Hedge Funds Weigh In On enGene

A number of institutional investors and hedge funds have recently modified their holdings of ENGN. Perceptive Advisors LLC raised its stake in enGene by 179.8% in the fourth quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company's stock valued at $52,998,000 after buying an additional 3,771,840 shares in the last quarter. Cormorant Asset Management LP boosted its position in shares of enGene by 72.1% during the 4th quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company's stock worth $36,120,000 after acquiring an additional 1,676,405 shares in the last quarter. Blue Owl Capital Holdings LP increased its holdings in shares of enGene by 2.5% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,360,937 shares of the company's stock valued at $30,349,000 after acquiring an additional 82,831 shares during the last quarter. Siren L.L.C. purchased a new position in shares of enGene in the 4th quarter valued at about $30,126,000. Finally, Braidwell LP raised its position in shares of enGene by 38.2% during the 4th quarter. Braidwell LP now owns 3,131,319 shares of the company's stock worth $28,276,000 after acquiring an additional 865,000 shares in the last quarter. Institutional investors and hedge funds own 64.16% of the company's stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.